MDAI Stats - Substance Search

Interaction Warnings

⚠ mdma

The neurotoxic effects of MDMA may be increased when combined with other stimulants.

⚠ cocaine

This combination may increase strain on the heart.

Receptor Profile

Receptor Actions

Inhibitors

Selective serotonin reuptake inhibitor (SSRI)

Other

Selective serotonin releasing agent (SSRA)

Minor norepinephrine releasing agent

Subjective Effects

Physical

Physical euphoria
Enhancement of touch
Sedation: The biggest difference between MDAI and MDMA is that due to a comparative lack of dopamine reuptake inhibition, MDAI primarily results in moderate sedation and therefore discourages physical activities such as running, dancing or climbing.
Spontaneous tactile sensations: The body high of MDAI can be described as a moderate to extreme euphoric, soft and warm tingling sensation that encompasses the entire body. It is capable of becoming overwhelmingly pleasurable at higher dosages.
Vibrating vision: At high dosages, a person's eyeballs may begin to spontaneously wiggle back and forth in a rapid motion, causing the vision to become blurry and temporarily out of focus (nystagmus).

Cognitive

The general head space of MDAI is described by many as one of euphoria and feelings of love or empathy. It contains a number of typical entactogenic cognitive effects.

Euphoria: Strong emotional euphoria and feelings of happiness are present within MDAI and are a direct result of serotonin and dopamine release.
Increased empathy, love and sociability: This particular effect is equally as pronounced, powerful and therapeutic as that of MDMA or 2C-B. It is the most obvious and noticeable effect within any MDAI experience and dominates the head space.
Acceleration of thought
Mindfulness

Sensory

The visual effects of MDAI only occur at higher dosages and are subtly psychedelic.

Visual · Distortions

Tracers

Visual · Enhancements

Increased visual acuity
Enhancement of colour

Forked from Subjective Effect Documentation by Josie Kins, August 2014. Via dose.wiki (CC0).

Toxicity

PsychonautWiki

MDAI and other similar drugs have been widely used in scientific research as they are able to replicate many of the effects of MDMA, but without causing the associated neurotoxicity. No tests have been performed on cardiovascular toxicity. There is currently no scientific data on the lethal dose of MDAI in humans and the exact toxic dosage is unknown. Due to its action as a serotonin reuptake inhibitor, overdoses of this substance would likely result in serotonin syndrome. It is strongly recommended that one use harm reduction practices when using this substance.

Addiction & dependence

Although no formal studies have been conducted, MDAI can be considered somewhat habit-forming with a low potential for abuse and is unlikely to be capable of causing psychological dependence among most users. This is because unlike traditional stimulants, MDAI does not increase concentrations of dopamine. If addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Effect Profile

Curated + 45 Reports

Psychedelic 1.4

Low visuals with mild body load

Visual Intensity×3

21.0

Headspace Depth×3

01.4

Auditory Effects×1

0

Body Load / Somatic Effects×1

51.7

Catalog BlueLight

Empathogen 5.1

Moderate euphoria and sensory enhancement with mild empathy, low stimulation

Empathy / Social Openness×3

54.8

Euphoria / Mood Elevation×2

67.3

Stimulation×1

37.9

Sensory Enhancement×1

63.5

Catalog BlueLight

Stimulant 4.8

Moderate euphoria with mild stimulation, low focus

Stimulation / Energy×3

4

Euphoria / Mood Lift×2

6

Focus / Productivity×2

2

Anxiety / Jitters×1

0

Based on reports from:

Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki MDAI The Drug Users Bible MDAI

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1h Half tolerance 10d Baseline ~14d

Experience Report Analysis

Erowid BlueLight

41 Reports

19 Single-substance

2010–2015 Date Range

39 With Age Data

17 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid + Bluelight

Effects aggregated from 45 experience reports (19 single-substance Erowid + 26 Bluelight)

45 Reports

103 Effects Detected

48 Positive

36 Adverse

19 Neutral

Effect Sentiment Distribution

Confidence Distribution

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Rows resting on fewer than 20 reports show a count (“3 of 7”) instead of a bar. Why 20?

Positive Effects 48

Euphoria 64.4% 88%

Stimulation 51.1% 81%

Sociability Enhancement 50.0% 83%

Music Enhancement 31.1% 91%

Love 30.8% 84%

Empathy 28.9% 87%

Body High 28.9% 78%

Libido Enhancement 26.9% 81%

Contentment 23.1% 82%

Tactile Enhancement 22.2% 80%

Joy 19.2% 85%

Color Enhancement 17.8% 82%

Emotional Openness 11.5% 85%

Closed-Eye Visuals 11.1% 75%

Morphing 7.7% 82%

Communication Enhancement 7.7% 82%

Depersonalization 7.7% 85%

Thought Disorganization 7.7% 78%

Memory Enhancement 7.7% 78%

Time Dilation 7.7% 82%

Adverse Effects 36

Insomnia 34.6% 82%

Anxiety 24.4% 82%

Jaw Clenching 22.3% 80%

Body Temperature Change 19.2% 75%

Nausea 17.8% 72%

Headache 15.6% 77%

Dry Mouth 15.4% 82%

Dysphoria 15.4% 81%

Sweating 11.1% 80%

Muscle Tension 8.9% 75%

Body Load 7.7% 75%

Temperature Sensitivity 7.7% 78%

Ataxia 7.7% 78%

Fear 7.7% 92%

Panic 7.7% 92%

Thought Loops 7.7% 80%

Dizziness 7.7% 80%

Ego Inflation 7.7% 75%

Disrupted Sleep Architecture 3.8% 70%

Irritability 3.8% 90%

Show 16 more adverse effects

Entity Imagery 3.8% 95%

Tremor 3.8% 75%

Itching 3.8% 75%

Temporal Disorientation 3.8% 75%

Memory Suppression 3.8% 75%

Frequent Urination 3.8% 85%

Sociability Suppression 3.8% 80%

Boredom 3.8% 75%

Paranoia 3.8% 80%

Derealization 3.8% 90%

Yawning 3.8% 70%

Restlessness 3.8% 70%

Stomach Cramps 3.8% 85%

Pain Enhancement 3.8% 85%

Emotional Release 3.8% 75%

Confusion 5 of 19 70%

Show 19 neutral or unclassified mentions

Sedation 33.3%

Drowsiness 26.9%

Pupil Dilation 23.1%

Tingling 19.2%

Chills 11.5%

Introspection 11.5%

Vivid Dreams 11.5%

Auditory Effects 8.9%

Hypersomnia 7.7%

Appetite Suppression 7.7%

Involuntary Movements 7.7%

Teeth Grinding 7.7%

Hot Flashes 7.7%

Sleep Paralysis 3.8%

Libido Suppression 3.8%

Emotional Lability 3.8%

Motor Suppression 3.8%

Blurred Vision 3.8%

Pupil Constriction 3.8%

Also reported in combinations. In the 22 MDAI reports where another drug was taken too, 1 (4.5%) mentions hospital, emergency services or an overdose, 0 (0.0%) a seizure and 0 (0.0%) psychosis. In the 19 single-substance reports: 0, 0 and 1. These are not in the figures above: they cannot be put down to MDAI alone, and a mention is not always something that happened to the writer.

Dosage Distribution

Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

Median: 162.5 mg IQR: 100.0–200.0 mg n=28

Real-World Dose Distribution

Erowid

From 69 of 70 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Oral (n=54)

Median: 145.0mg 25th: 100.0mg 75th: 200.0mg 90th: 241.0mg

Insufflated (n=13)

Median: 45.0mg 25th: 25.0mg 75th: 50.0mg 90th: 95.0mg

Common Combinations

Most co-occurring substances, as a share of all 41 reports filed under MDAI; whiskers are 95% intervals

Form / Preparation

Most common forms and preparations, as a share of the 36 reports that give one; whiskers are 95% intervals

Body-Weight Dosing

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Median: 2.108 mg/kg IQR: 1.497–2.426 mg/kg n=26

Redose Patterns

Redosing behavior across 36 reports

55.6% Redosed

1.9 Avg Doses

60m Median Interval

Legal Status

Country	Status	Notes
Austria	MDAI is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Brazil	MDAI is illegal to possess, produce and sell under Portaria SVS/MS nº 344.
China	As of October 2015 MDAI is a controlled substance in China.
Denmark	MDAI is illegal in Denmark as of September 2015.
Finland	Scheduled in the "government decree on psychoactive substances banned from the consumer market".
Germany	MDAI is controlled under the NpSG ( New Psychoactive Substances Act ) as of November 26, 2016.	Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan	MDAI is a controlled substance in Japan effective March 30th, 2013.
Switzerland	As of December 2011 MDAI is a controlled substance in Switzerland.
United Kingdom	MDAI is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
United States	legal	Caution : All legal information should be verified through other sources. see below U.S. FEDERAL LEGAL SUMMARY MDAI - REGULATED: No - STATUS: Not Approved ForHuman Consumption - SCHEDULE: Un-Scheduled MDAI is uncontrolled in the United States under federal law. This means it is generally considered legal to buy, possess, and distribute (sell, trade or give). If sold as a supplement, sales must conform to U.S. supplement laws. If sold for consumption as a food or drug, sales are regulated by the FDA. It is possible that it would be considered an analog in which case, sales for human consumption or possession with the intent to ingest could be prosecuted under the Federal Analogue Act or state analog acts. U.S. STATE LAW

MDAI Stats & Data